Advanced Techniques in Biology & Medicine
Open Access

Prevention and Treatment Involved in Anthrax

Finnie Paul^{* *}Correspondence: Finnie Paul, Department of Neurology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, Email:

Author info »

Description

Bacillus anthracis causes an infection known as anthrax. The four possible manifestations are skin, lungs, intestinal, and injectable. After contracting the virus, symptoms might start anywhere from a day to more than two months later. The skin initially appears as a small blister with surrounding edema, which frequently develops into an ulcer with no pain and Shortness of breath, a fever, and chest pain are symptoms of the inhalation variant. Intestinal symptoms include vomiting, nausea, diarrhea and stomach pain. Fever and an abscess at the injection site are symptoms of the injectable form.

Treatment

With the exception of skin exudates from cutaneous anthrax, anthrax cannot be transmitted from one person to another. However, anthrax spores could get on someone's skin, clothes, or body. People can be effectively decontaminated by being thoroughly washed down with antibacterial soap and water. Bleach or another antimicrobial agent is used in the treatment of wastewater. Formaldehyde works better than chlorine bleach at eliminating spores and vegetative cells from surfaces. Spores can be effectively destroyed by burning garments. If contacts of anthrax patients have been decontaminated, there is no need to immunize, treat, or isolate them unless they were also exposed to the same source of infection.

Antibiotics

Early antibiotic treatment is crucial for anthrax; postponing treatment drastically reduces survival chances. Large dosages of intravenous and oral antibiotics, such as fluoroquinolones (ciprofloxacin), doxycycline, erythromycin, vancomycin, or penicillin, are used as treatment for anthrax infection and other bacterial infections. Drugs including ciprofloxacin, doxycycline, and penicillin are approved by the FDA. Early antibiotic prophylactic treatment is essential in suspected cases of pulmonary anthrax in order to avert potential fatality. Although numerous attempts have been made to create novel anthraxmedications, existing medications work well when administered promptly.

Monoclonal antibodies

A monoclonal antibody called raxibacumab neutralizes the toxins generated by B. anthracis. A monoclonal antibody that neutralizes B. anthracis' toxins was used in a second anthrax treatment that the FDA approved in March 2016. In conjunction with the proper antibacterial medications, obiltoxaximab is approved for the treatment of inhalational anthrax as well as for prevention when appropriate or available alternative medicines are unavailable.

Prevention

When a dead person is suspected of carrying anthrax, precautions are made to prevent contact with the skin and any bodily fluids that may have leaked through normal body holes. Strict quarantine should be maintained for the body. In order to determine whether anthrax is the cause of death, a blood sample is obtained, sealed in a container, and examined in an authorized laboratory. To stop the spread of anthrax spores, the body should be placed in an airtight body bag and burned. Although the culture of the organism is still the golden standard for diagnosis, microscopic viewing of the encapsulated bacilli, typically in extremely large numbers, in a blood smear stained with polychrome methylene blue (McFadyean stain), is totally diagnostic. To avoid the possibility of others becoming contaminated, the body must be completely isolated.

Vaccines

In the history of medicine, anthrax vaccines for both cattle and humans have played a significant role. The first efficient vaccination was created in 1881 by the French scientist Louis Pasteur. The Soviet Union created human anthrax vaccines in the late 1930s.

Acellular vaccinations are currently used to prevent human exposure to anthrax in the United States, while live vaccines are used in Russia. All currently available anthrax vaccines exhibit significant local and systemic reactogenicity (erythema, induration, pain, fever), and roughly 1% of patients experience serious adverse events. The FDA has granted permission to Bio Thrax, which was previously given in a six-dose primary series at 0, 2, 4 weeks, 6, 12, and 18 months, with annual boosters to maintain immunity. The FDA allowed skipping the dose given in week two in 2008, leading to the current five-dose series that is advised. Recombinant live vaccines and recombinant sub unit vaccinations are examples of new second-generation vaccines now under study.

Conclusion

When handling the body, protective, impermeable attire such as rubber gloves, an apron made of rubber, and rubber boots without holes are used. No flesh should be exposed, especially if it has any sores or scratches. Although disposable personal protective equipment preferred, autoclaving can be used to decontaminate if that option is not available. After use, used, disposable equipment is burned or buried. All infected clothes or bedding is segregated and handled as biohazard rubbish in double plastic bag.